Clinical Report: Tackling Trachoma in Ethiopia

Overview

The FLAME trial evaluated the efficacy of fluorometholone 0.1% as adjunctive therapy post-trachomatous trichiasis surgery in Ethiopia. Results showed no significant reduction in postoperative trachomatous trichiasis incidence compared to placebo, indicating that the use of this steroid may not be beneficial in this context. This highlights the need for alternative strategies to improve surgical outcomes.

Background

Trachomatous trichiasis is a leading cause of preventable blindness, particularly in endemic regions like Ethiopia. Despite surgical interventions, high relapse rates pose challenges for public health efforts aimed at eliminating this condition. Understanding effective postoperative treatments is crucial for improving surgical outcomes and patient satisfaction.

Data Highlights

No significant difference in cumulative postoperative trachomatous trichiasis incidence was observed between the fluorometholone and placebo groups, both at 12 months (13.4%). This suggests that the adjunctive use of fluorometholone does not provide a clinical advantage in preventing relapse.

Key Findings

• The FLAME trial involved 2,410 participants, with a high follow-up rate of approximately 98% at 12 months, ensuring robust data reliability.
• Cumulative incidence of postoperative trachomatous trichiasis was 13.4% in both the fluorometholone and placebo groups, indicating no therapeutic benefit.
• No significant safety concerns were noted regarding intraocular pressure rise or cataract progression associated with fluorometholone use.
• Patient satisfaction post-surgery was extremely high, with over 99% reporting satisfaction.
• The study suggests that improving surgical techniques and training may be more effective than adjunctive steroid therapy in reducing relapse rates.

Clinical Implications

Ophthalmologists in trachoma-endemic regions should consider focusing on enhancing surgical techniques and training rather than relying on adjunctive steroid therapies like fluorometholone. This approach may lead to better long-term outcomes for patients undergoing trachomatous trichiasis surgery, emphasizing the critical role of surgical quality.

Conclusion

The FLAME trial's findings indicate that while fluorometholone is safe for use post-surgery, it does not effectively reduce the incidence of postoperative trachomatous trichiasis. Future efforts should prioritize surgical quality and training, and further research is needed to explore alternative postoperative treatments.

References

1. Ophthalmology Management, Global Outreach: Going Further, 2025 -- Training for Sustainable Surgical Outcomes
2. Glaucoma Physician, Glaucoma in Africa, 2017 -- Addressing the Burden of Glaucoma
3. Corneal Physician, Challenges and Opportunities in Eliminating Corneal Blindness, 2021 -- Collaborative Approaches to Eye Health
4. Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME), ScienceDirect, 2025 -- Major Trial Findings
5. Outcomes of posterior lamellar tarsal rotation vs bilamellar tarsal rotation for trachomatous trichiasis, PLOS Neglected Tropical Diseases, 2025 -- Surgical Technique Comparison
6. Contact Lens Spectrum — treatment plan
7. Organizing Trichiasis Surgical Outreach
8. Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME): a parallel, double-blind, randomised controlled field trial in the Jimma Zone, Ethiopia - ScienceDirect
9. Outcomes of posterior lamellar tarsal rotation vs bilamellar tarsal rotation for trachomatous trichiasis | PLOS Neglected Tropical Diseases